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Abstract 
Background: Radix Salviae Miltiorrhizae (RSM), a well‑known traditional Chinese medicine, has been shown to inhibit 
tumorigenesis in various human cancers. However, the anticancer effects of RSM on human hepatocellular carcinoma 
(HCC) and the underlying mechanisms of action remain to be fully elucidated.
Methods: In this study, we aimed to elucidate the underlying molecular mechanisms of RSM in the treatment of 
HCC using a network pharmacology approach. In vivo and in vitro experiments were also performed to validate the 
therapeutic effects of RSM on HCC.
Results: In total, 62 active compounds from RSM and 72 HCC‑related targets were identified through network 
pharmacological analysis. RSM was found to play a critical role in HCC via multiple targets and pathways, especially 
the EGFR and PI3K/AKT signaling pathways. In addition, RSM was found to suppress HCC cell proliferation, and impair 
cancer cell migration and invasion in vitro. Flow cytometry analysis revealed that RSM induced cell cycle G2/M arrest 
and apoptosis, and western blot analysis showed that RSM up‑regulated the expression of BAX and down‑regulated 
the expression of Bcl‑2 in MHCC97‑H and HepG2 cells. Furthermore, RSM administration down‑regulated the expres‑
sion of EGFR, PI3K, and p‑AKT proteins, whereas the total AKT level was not altered. Finally, the results of our in vivo 
experiments confirmed the therapeutic effects of RSM on HCC in nude mice.
Conclusions: We provide an integrative network pharmacology approach, in combination with in vitro and in vivo 
experiments, to illustrate the underlying therapeutic mechanisms of RSM action on HCC.
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Background
Hepatocellular carcinoma (HCC) is the most frequent 
primary liver malignancy and is a major health problem 
worldwide [1]. In 2017, 782,000 cases were diagnosed 
and there were 746,000 deaths, and the incidence of HCC 
in worldwide continued to increase, with an age-adjusted 
incidence rising 10 per 100,000 individuals [2]. Chronic 
liver disease and cirrhosis remain the most significant 
risk factors for the development of HCC, of which hepa-
titis virus infection and excessive alcohol intake are the 
leading risk factors worldwide [3–5]. As patients in the 
early stages of HCC are generally asymptomatic, it is 
mainly diagnosed at an advanced stage, when the con-
dition is incurable. While current treatment regimens 
have increased survival time for patients, the utilization 
of sorafenib has only increased survival by a few months 
[6]. In addition, sorafenib is associated with severe side-
effects, which have limited the clinical use of the drug. 
Hence, new medicines with good efficacy and tolerability 
are urgently demanded.
In recent years, researchers have focused on developing 
a Traditional Chinese Medicine (TCM) for the treatment 
of HCC. Radix Salviae Miltiorrhizae (RSM), also known 
as Danshen in Chinese, is a widely used Chinese medicine, 
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which has been applied clinically for more than 1000 years. 
Research has shown that RSM possesses a variety of phar-
macological effects, including anti-platelet aggregation, 
anti-hypertension, anti-inflammation, and improvement 
of cerebral ischemia reperfusion injury, as well as cardio-
vascular protection [7–10]. Evidence accumulated in the 
last decade has demonstrated that RSM also demonstrates 
a significant anti-cancer effect against breast cancer, clear 
cell ovarian carcinomas, promyelocytic leukemia, and 
HCC [11–13]. Bae et  al. [14] showed that S. miltiorrhiza 
Bunge might present a significant anticancer effect by 
inhibiting prostate cancer cell proliferation and inducing 
prostate cancer cell apoptosis. Kim et al. [15] revealed that 
S. miltiorrhiza extracts inhibited TPA-induced MCF-7 
cell invasion and Matrix metalloproteinase-2 (MMP-9) 
expression by blocking the transcriptional activation of 
AP-1. The main active ingredients in Radix S. miltiorrhizae 
can be classified into two parts: hydrosoluble salvianolic 
acids (salvianolic acid A, salvianolic acid B, danshensu, 
rosmarinic acid) and liposoluble tanshinones (tanshinone 
IIA [TIIA], cryptotanshinone [CT], dihydrotanshinone I 
[DH-TI], tanshinone I [TI]). Previous studies have shown 
that TIIA is an active component of RSM, which inhib-
its human gastric cancer cells by decreasing HER2 and 
VEGFR protein levels, inhibits the Ras/Raf/MEK/ERK 
signaling pathway, and induces caspase-3, PARP activa-
tion, and apoptosis [16]. TIIA also decreases human can-
cer cell invasion and metastasis in the nude mice model. In 
addition, salvianolic acid B induces autophagy and exerts 
antitumor effects in colorectal cancer cells via inhibition of 
the AKT/mTOR pathway [17]. RSM and its active compo-
nents may serve as a promising anti-cancer therapy; how-
ever, its pharmacological mechanisms of action have not 
been fully elucidated. Therefore, the aim of our research 
was to explore the anti-HCC effects of RSM extracts and 
explore the underlying mechanisms.
TCM is typically associated with multiple targets, mul-
tiple pathways, and multiple mechanisms of actions, mak-
ing it difficult to elucidate its effects. These greatly restrict 
the process of modernization and internationalization of 
Chinese medicine. The concept of network pharmacology 
derived from the introduction of systems biology and the 
application of bioinformatics, along with “omics” theory 
involved in modern genomic, proteomic, and metabolomic 
development. Network pharmacology was developed 
based on the rapid development of systems biology and 
computer technology. Based on the “disease-gene-target-
drug” interaction network, network analysis was used to 
observe the intervention and influence of drugs on the 
disease network, and the synergistic effects of multiple 
drugs were determined [18, 19]. In recent years, network 
pharmacology has emerged as a powerful tool that can be 
integrated with pharmacology. It provides a novel tool and 
concept to evaluate the efficacy mechanisms of action of 
drugs. Combining the target database of TCM in various 
diseases with molecular verification provides evidence for 
the molecular target and its mechanism of action [20–23]. 
Thus, this study combines network pharmacology with 
experimental validation to clarify the potential mechanism 
of RSM against HCC and suggests a novel promising ther-
apeutic strategy for the treatment of HCC (Fig. 1).
Methods
The Minimum Standards of Reporting Checklist con-
tains details of the experimental design, statistics, and 
resources used in this study.
Compound database building
Traditional Chinese Medicine Systems Pharmacology 
(TCMSP) is a unique system pharmacology platform of 
Chinese herbal medicines, which captures the relation-
ships between drugs, targets, and diseases. A catalog of 
chemical ingredients was generated from related articles 
and the natural products database of TCMSP (http://lsp.
nwu.edu.cn/tcmsp .php) [24].
Pharmacokinetic prediction
Absorption, distribution, metabolism, and excretion 
(ADME), an in silico evaluation model in pharmacoki-
netic research, was employed to select drugs. In this 
study, an in silico ADME-systems evaluation model 
including drug-likeness (DL) and oral bioavailability 
(OB) was applied to evaluate the potential bioactive com-
ponents of RSM. OB is an essential parameter of orally 
administered drugs, and is used to assess the pharma-
cokinetics and drug-forming properties of drugs in vivo. 
The TCMSP database calculated OB values using OBio-
avail1.1 [25]. Drug-likeness (DL) is a qualitative concept 
used in drug design to evaluate how “drug-like” a mol-
ecule is with respect to factors such as bioavailability. 
DL is estimated from the molecular structure before the 
substance is synthesized and tested. To identify drug-like 
ingredients, the Tanimoto coefficient, T (A, B) = (A × B)/ 
(|A|2 + |B|2 − A × B) was applied to calculate the DL val-
ues of each ingredient in RSM by a database-dependent 
model. A presents the new compound, and B displays 
the average molecular properties of all compounds in the 
DrugBank database (http://www.drugb ank.ca). In this 
study, molecules with DL ≥ 0.18, OB ≥ 30% were used for 
subsequent research, and others were excluded.
Compound targets for RSM
A systematic drug targeting tool was used to predict 
the targets of candidate molecules, which efficiently 
combines genomic, chemical, and pharmacological 
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information for drug targeting through Random Forest 
(RF) and Support Vector Machine (SVM) methods [26]. 
In this study, compound-target interactions with a RF 
score ≥ 0.7 and an SVM score ≥ 0.8 were regarded as 
potential targets for active molecules.
Related targets of HCC
HCC-related genes were collected from two databases. 1. 
GeneCards (http://www.genec ards.org) [27] is a search-
able, integrative database of human genes that provides 
genomic, proteomic, transcriptomic, genetic, and func-
tional information on all known and predicted human 
genes. The database automatically integrates gene-centric 
data from ~ 125 web sources, such as HGNC, NBCI, 
and Ensemble. 2. Online Mendelian Inheritance in Man 
(OMIM) (http://omim.org/) [28] is a comprehensive, 
authoritative compendium of human genes and genetic 
phenotypes, which is freely available and updated daily. 
We searched these databases with the keywords “hepato-
cellular carcinoma” and “hepatocarcinoma”.
Construction of a protein–protein interaction (PPI) network
PPI data were derived from String (http://strin g-db.org/, 
ver.10) [29], an online database of known and predicted 
protein-protein interactions with the species limited to 
“Homo sapiens” and a confidence score > 0.4.
Fig. 1 Flowchart showing the systems pharmacology approach for determining the pharmacological mechanisms of action of Radix Salviae 
Miltiorrhizae (RSM) on human hepatocellular carcinoma (HCC) by integrating target identification, network analysis, and experimental validation
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Gene ontology (GO) and pathway enrichment analysis
The Database for Annotation, Visualization, and Inte-
grated Discovery (DAVID; http://david .abcc.ncifc rf.gov/) 
[30, 31] was employed in GO and Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway enrichment 
analysis.
Network construction
The network was constructed as follows: (1) compound-
compound target network of RSM; (2) PPI network. All 
visualized networks were constructed using software 
Cytoscape (http://cytos cape.org/, ver. 3.6.0), an open 
software platform for visualizing biological pathways, 
molecular interaction networks, and integrating these 
networks with annotations, gene expression profiles, and 
other state data.
Reagents and antibodies
Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s 
medium (DMEM), and penicillin–streptomycin were 
provided from Gibco. Cell culture supplies were obtained 
from Costar (Corning, USA). Antibodies, including anti-
PI3-kinase p85-α (ab182651), anti-Bcl-2 (ab59348), HRP-
conjugated goat anti-rabbit (ab6721), and anti-mouse IgG 
(ab6789) were from Abcam (Cambridge, UK). Antibod-
ies, including anti-EGFR (#4267), anti-Bax (#2772), anti-
AKT (#9272), anti-p-AKT (#4058), and β-actin (ab8227) 
were obtained from Cell Signaling Technology (Boston, 
USA).
Preparation of ethanol extract from RSM
Dried roots of. S. miltiorrhiza Bunge were obtained from 
Xing Yuan Chun Pharmacy (Guangzhou, China). The 
original herb was identified by the Department of Tradi-
tional Chinese Medicine, Guangzhou University of Tra-
ditional Chinese Medicine, China. A voucher specimen 
was deposited at the public Herbarium of the Depart-
ment of Traditional Chinese Medicine, Guangzhou Uni-
versity of Traditional Chinese Medicine. Samples (500 g) 
of dried roots of S. miltiorrhiza Bunge were extracted 
with 5  L of 95% ethanol using a refluxing method and 
then filtered. The filtrates were evaporated and lyophi-
lized to obtain a dried powder. Dried powder obtained 
from the ethanol extracts of RSM was stored in 4 °C for 
future use.
HPLC analysis
Ethanol extracts of Radix S. miltiorrhizae were qualita-
tively analyzed by high-performance liquid chromatogra-
phy (HPLC). Shimadzu HPLC systems (LC-20AT, Japan), 
equipped with a CM-20A system controller, an infusion 
pump (LC-20A, Japan), an automatic sampler (Sil-20A, 
Japan), and a CTO-20A column temperature chamber, 
were used for chromatographic analysis. Ethanol extracts 
of Radix S. miltiorrhizae, TIIA, TI, CT, and DH-TI were 
separated on WondaSil C18–WR (250  mm × 4.6  mm, 
5 μm) at 30  °C. The sample was eluted at a flow rate of 
1  mL/min in a gradient elution program of A (acetoni-
trile) and B (water): 0–0.01  min (42% B); 0.01–25  min 
(10% B); 25–27  min (42% B); 27–35  min (42% B). The 
injection volume was 20 μL. Monitoring was performed 
at 270 nm with an SPD-M20A diode array detector. TIIA, 
TI, CT, and DH-TI.
Cell lines and culture
Human HCC cell lines MHCC97-H and HepG2 were 
obtained from the Chinese Academy of Sciences cell 
bank, Beijing, China. Cells were cultured in DMEM/high 
glucose medium with 10% FBS and 100 U/mL penicil-
lin–streptomycin, and incubated at 37  °C in a 5%  CO2 
incubator.
Cell viability assay
Cells were seeded into a 96-well plate at a density of 
1 × 105/mL (100  μL/well) and cultured overnight. Cell 
viability was evaluated by MTT (5 mg/mL) at 24 h. Fol-
lowing the addition of 10  μL MTT per well, cells were 
incubated for 4  h at 37  °C. The medium was removed, 
and 150 μL of dimethyl sulfoxide (DMSO) was added to 
each well. The optical density (OD) value was detected 
at the wavelength of 490  nm using a microplate reader 
(Thermo Fisher, USA) after thoroughly shaking the plate.
Colony formation assay
One-thousand cells were seeded in a six-well plate 
and cultured in DMEM containing 10% FBS. The cul-
ture medium was replaced every 3  days. After 14  days, 
the colonies were fixed with 4% paraformaldehyde for 
10–15  min and stained with crystal violet solution for 
10 min. Cell colonies in each well that had ≥ 50 cells per 
colony were counted after washing with water.
Wound‑healing assay
MHCC97-H and HepG2 cells (4 × 105 cells/well) were 
seeded in a 6-well plate for use in wound-healing assays. 
After the cells reached full confluence, the cell monolayer 
was scratched using a 10 μL pipette tip and the medium 
was replaced with medium containing 0.1% FBS. The 
scratches were imaged at 0 and 48 h following scratching, 
using a 10× objective microscope. The cell migration rate 
was calculated as the distance of the wound recovered 
versus that of the original wound.
Transwell migration and invasion assay
A Transwell invasion and migration assay was performed 
to determine cell migration and invasion capacities. Cells 
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(2 × 105) in serum-free medium were seeded onto the 
upper chamber after drug treatment, and the bottom 
chamber was placed into DMEM medium containing 
10% FBS. After 24 h incubation, cells on the upper sur-
face of the membrane were removed and the invading 
cells were fixed in 4% paraformaldehyde for 10 min and 
stained with crystal violet solution for 5 min. A cell inva-
sion assay was performed similarly, except that 60 μL of 
Matrigel (BD Biosciences, USA) diluted 1:8 with serum-
free medium, was added to each well overnight before 
the cells were seeded onto the membrane. The number of 
invading cells was analyzed statistically using three inde-
pendent experiments and the results were averaged from 
five image fields.
Flow cytometry for cell cycle analysis
MHCC97-H and HepG2 cells were harvested by trypsini-
zation following treatment with RSM (0, 5, 10, and 20 μg/
ml) for 24 h. Cells were fixed in 70% cold ethanol at 4 °C 
overnight after washing twice in cold PBS. Then, the cells 
were washed twice with cold PBS, centrifuged at 1000g 
for 3–5  min to precipitate cells and then treated with 
500  μL staining buffer (PI/RNase A = 9:1) at 37  °C for 
40 min in the dark. A flow cytometer was used to analyze 
the samples and the results were analyzed using Modifit 
acquisition software.
Flow cytometry for analysis of cell apoptosis
Apoptosis was analyzed using an Annexin V-FITC apop-
tosis detection kit (Vazyme, China). MHCC97-H and 
HepG2 cells were seeded at a density of  106 cells/well in 
6-well plates. After 24  h treatment with RSM, the cells 
were analyzed using an Annexin V-FITC kit to detect 
apoptosis. The apoptotic cells were detected by flow 
cytometry (BD Biosciences, USA).
Western blot
Cell proteins were extracted after 24  h incubation with 
the indicated concentrations of RSM. The cells were 
homogenized and lysed in sample buffer (0.5  M Tris/
HCl pH 6.8, 50% glycerol, 10% sodium dodecyl sulphate 
[SDS], 1: 100 protease and phosphatase inhibitor cock-
tail). Total cell lysates were separated by 10% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and t transferred onto polyvinylidene dif-
luoride (PVDF) membranes (Bio-Rad, USA). Then, the 
membranes were blocked with 5% bovine serum albu-
min for 2 h at room temperature and incubated with the 
appropriate primary antibody solution including EFGR 
(1:1000), anti-PI3-kinase p85-α (1:1000), anti-Bcl-2 
(1:1000), anti-Bax (1:1000), anti-AKT (1:1000), anti-p-
AKT (1:1000), and β-actin (1:8000) overnight at 4 °C. The 
membranes were incubated with HRP-conjugated goat 
anti-mouse or anti-rabbit IgG (1:1000) for 2  h at room 
temperature and the protein bands were visualized by an 
ECL kit.
Orthotopic transplantation of HCC in nude mice
Five-week-old BALB/c male nude mice were obtained 
from the Experimental Animal Center of Guangzhou 
University of Traditional Chinese Medicine. MHCC-
97L-luciferase cells (5 × 106/100  μL) were subcutane-
ously injected into the nude mice. Once it reached a 
diameter of 1 cm, the subcutaneous tumor was cut into 
approximately 1 mm3 pieces and implanted into the left 
liver lobes of another group of nude mice. Mice with 
luciferase signals from liver HCC tumors were analyzed 
by Xenogen IVIS after 7 days. Surviving mice, with suc-
cessfully implanted tumors confirmed by in vivo imaging 
(Xenogen Corp. USA), were randomly divided into three 
groups: a control saline group (n = 5), an RSM low dose 
group (n = 5, 100  mg/kg/day), and an RSM high dose 
group (n = 5, 200 mg/kg/day). Nude mice were anesthe-
tized with sodium pentobarbital (50  mg/kg i.p.) at the 
end of the study. To quantify tumor progression, in vivo 
imaging of liver tumors was performed by Xenogen IVIS 
2, 3, and 4  weeks after tumor implantation. All animal 
protocols in the study were performed in accordance 
with international ethical guidelines and the National 
Institutes of Health Guide concerning the Care and Use 
of Laboratory Animals. All experiments and the use of 
animals in this study was approved by the Institutional 
Animal Care and Use Committee of Guagnzhou Univer-
sity of Traditional Chinese medicine, China.
Statistical analysis
All statistical analyzes were performed by Statistical 
Product and Service Solutions (SPSS) 20.0 software. 
One-way analysis of variance (ANOVA) followed by the 
Dunnett’s post hoc test was used for multiple groups 
comparisons. Our data are expressed as mean ± stand-




The constituents of the ethanol extracts of RSM were 
analyzed and identified by HPLC. As shown in Fig.  2, 
compounds represented by four main peaks of the HPLC 
chromatogram were identified as TIIA, TI, CT, and 
DH-TI.
Chemical composition and targets of RSM
In total, 202 compounds were collected from RSM. Sixty-
five candidate molecules were obtained with OB ≥ 30% 
and DL ≥ 0.18. Notably, the OB values of salvianolic acid 
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B and salvianolic acid A were lower than 30%; however, 
both are widely used to treat liver disease in  vivo [32, 
33] and in vitro [34, 35]. Therefore, these two molecules 
were also employed as candidate molecules, making a 
total of 67 active ingredients. Detailed information on 
active molecules in RSM is presented in Additional file 1: 
Table S1. Among the 67 compounds obtained, five candi-
date molecules had no targets. Finally, 62 chemical com-
pounds yielded 101 putative targets. The details of these 
targets are shown in Additional file 2: Table S2.
Compound‑compound targets network analysis
RSM exerts a wide range of biological and pharmaco-
logical effects through a variety of molecules and targets. 
To elucidate the complex interactions of RSM constitu-
ents and their corresponding targets at the system level, 
we constructed a network based on the potential com-
pounds of RSM and candidate targets. The network 
consists of 163 nodes (62 compound nodes and 101 com-
pound target nodes) and 1322 edges (Fig. 3). In Fig. 3, red 
V represents RSM, pink hexagons represent compounds 
of RSM, and blue circles represent compound targets. 
The average value (the number of connections that each 
node has to other nodes) of the candidate compounds 
was 21.3, and the average value of the 19 compounds was 
greater than 30, indicating that RSM modulates multiple 
targets by multiple components to exert various thera-
peutic effects. These are potential active compounds 
of RSM due to their key positions in this network: 
tanshinone IIA (degree = 40) and cryptotanshinone 
(degree = 35). Taking tanshinone IIA as an example, this 
molecule exhibits extensive pharmacological activities, 
with anti-coagulation, anti-apoptosis, and anti-oxidative 
properties, by mediating the activation of retinoid X 
receptor alpha 1, inducible nitric oxide synthase, and 
BCL2, the apoptosis regulator [36]. Additionally, the 
results suggested that many targets were hit by multiple 
compounds in the network. ESR1, AR, and PTGS2 are 
targeted by 58, 55, and 50 compounds. These targets play 
critical roles in processes such as cell proliferation and 
inflammation [37, 38].
Identification of candidate protein targets associated 
with HCC
Overall, 5730 HCC-related targets were obtained from 
the GeneCards database, and 153 HCC-related targets 
were collected from the OMIM database. In total, 5617 
HCC-related targets were identified following the dele-
tion of duplicate targets. To elucidate the pharmacologi-
cal mechanism of action of RSM in human HCC, a PPI 
network was determined and GO and pathway enrich-
ment analysis was performed on the common targets 
of RSM and HCC. Seventy-two common targets were 
obtained. The details of targets are shown in Additional 
file 3: Table S3.
PPI network
We constructed a protein-protein interaction network, 
which denoted the relationship among 72 HCC-related 
targets to determine the importance of candidate targets. 
One target was no gene-gene interaction, and another 
target was not found in the above two databases. The net-
work contained 70 nodes and 571 edges (Fig. 4). A hub 
node was defined as two-times greater than the aver-
age node degree in the network [39]. The average node 
degree (the number of targets associated with it) of the 
Fig. 2 RSM analyzed by HPLC. From right to left, the four major peaks represent: tanshinone IIA, tanshinone I, cryptotanshinone, and 
dihydrotanshinone I
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Fig. 3 Compound‑compound target network. RSM consists of 62 compounds and 101 compound targets (red V represents RSM; pink hexagons 
represent compounds of RSM; blue circles represent compound targets)
Fig. 4 Protein‑protein interaction (PPI) network. The nodes get larger with increasing degree. Edges: PPIs between putative targets of RSM and their 
interactive partners; blue round rectangular nodes: common targets of RSM and HCC; dark blue round rectangular nodes: hub targets of RSM and 
HCC
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HCC-related targets was 32.6. Therefore, the hub nodes 
including TNF, PIK3CG, VEGFA, IL6, EGFR, MAPK1, 
JUN, TP53, BCL2, and ESR1 contained over 32.6 degrees. 
The number of edges per node as somewhat large (44 in 
TP53, 43 in JUN, 40 in IL6, 39 in MAPK1, 39 in VEGFA, 
38 in ESR1, 38 in EGFR, 37 in TNF, 35 in PIK3CG, 
and 34 in BCL2). The network results suggest that the 
abovementioned genes may represent hub genes for the 
development of HCC. EGFR is expressed at high levels 
in cancer cells, and its activation EGFR appears to be 
important for tumor progression and growth [40]. Thus, 
RSM may act on HCC by targeting EGFR.
Gene ontology and pathway enrichment analysis 
for targets
To elucidate the biological characteristics of puta-
tive targets, functional enrichment analysis was per-
formed for the target genes. The results, and detailed 
information on the GO targets, and pathways are 
shown in Additional file 4: Table S4. The 15 most sig-
nificantly enriched terms in biological process (BP), 
molecular function (MF), and cellular component 
(CC) categories (P < 0.05) are listed in Fig. 5. Figure 5 
indicates that RSM may regulate cell proliferation, cell 
growth, and apoptotic processes, via protein binding, 
enzyme binding, and protease binding in the plasma 
membrane, nucleus, and cytoplasm to exert anti-
HCC potential. A pathway analysis was performed to 
explore the underlying mechanisms of RSM action 
for treatment of HCC. The results demonstrated that 
68 targets were mapped into the 99 KEGG pathways, 
including pathways in cancer, PI3K/AKT signaling, 
and proteoglycans in cancer, while four of 72 targets 
were not mapped into pathways. The 15 most signifi-
cant pathways (P < 0.05) are shown in Fig.  6. Cancer 
signaling pathways displayed the highest number of 
target connections (degree = 22), followed by PI3K/
AKT signaling pathways with 17 targets, and pro-
teoglycans in cancer with 12 targets. The PI3K/AKT 
pathway is closely related to the proliferation, differ-
entiation, apoptosis, migration, and adhesion of tumor 
cells involving multiple targets, including EGFR, 
BCL2, GSK3B, CDK2, and CDK4. Therefore, the data 
provided theoretical evidence that RSM may activate 
P13K/AKT signaling pathways in HCC. 
RSM inhibits the proliferation of human HCC cells
To explore the effects of RSM on human HCC cells, 
MHCC97-H and HepG2 cells were incubated with 
increasing doses of RSM for 24  h. Cell viability was 
Fig. 5 Gene ontology enrichment analysis of identified related targets. a Biological process, b cellular component, c molecular function
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assessed by MTT assay. The results of the MTT assay 
suggested that RSM significantly inhibited the viability 
of MHCC97-H and HepG2 cells (Fig. 7a, b). In a colony 
formation assay, RSM decreased colony formation at all 
indicated doses (Fig.  7c, d). These data suggested that 
RSM can inhibit HCC cell viability and proliferation.
RSM induces cellular apoptosis and arrests cell cycle 
progression in the G2/M phase
We next investigated whether RSM affects cell cycle 
arrest and cellular apoptosis via flow cytometry. Admin-
istration of RSM at 5–20  μg/mL led to a significant 
increase in the number of apoptotic cells (Fig.  8a). 
As shown in Fig.  8b, we also assessed RSM-induced 
apoptosis by western blot. The results suggested that 
the expression of the apoptosis-related protein Bcl-2 
decreased and Bax increased after treatment with RSM. 
Furthermore, RSM induced cell cycle arrest in MHCC97-
H and HepG2 cells  (Fig.  8c). These results suggest that 
RSM might induce apoptosis and cell cycle arrest.
RSM inhibits human HCC cell migration and invasion
To investigate the migratory ability of RSM in human 
HCC cells, wound healing and Transwell migration 
assays were performed. As shown in Fig.  9a, unlike in 
the control group, migration was markedly inhibited in 
cells treated with RSM. The Transwell migration assay 
also showed that RSM treatment inhibited the migration 
of cells in a dose–dependent manner (Fig.  9b). Moreo-
ver, the treatment of MHCC97-H and HepG2 cells with 
5–20  μg/mL RSM for 24  h inhibited the number of 
Fig. 6 Pathway analysis for identified related targets
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invading cells (Fig. 9b). These results confirmed that RSM 
inhibited the migration and invasion of cancer cells.
RSM down‑regulates EGFR expression, and attenuates 
PI3K/AKT signaling in human HCC cells
The network pharmacology results described above, 
suggested that the EGFR and PI3K/AKT signaling path-
ways might account for the mechanism of RSM action 
in on HCC. Therefore, we evaluated the expression lev-
els of EGFR, PI3K, AKT, and p-AKT by western blot. As 
shown in Fig.  10, the expression of EGFR decreased in 
both MHCC97-H and HepG2 cells treated with 5–20 μg/
mL RSM for 24  h. Next, we assessed the protein lev-
els of PI3K, AKT, and p-AKT. The results indicated that 
RSM significantly decreased the expression of p-AKT 
and PI3K, whilst total AKT expression was not changed. 
Taken together, these results suggest that the effect of 
RSM in HCC might be related to the EGFR and PI3K/
AKT signal transduction pathways in human HCC cells.
RSM inhibits the growth of liver tumors in nude mice 
following orthotopic liver transplantation
We explored the anti-HCC potential of RSM in  vivo. 
Implantation of MHCC-97L-luciferase facilitated moni-
toring of liver cancer progression by bioluminescence 
imaging to quantify bioluminescence emitted from can-
cer cells. Three weeks after implantation, there was a sig-
nificant inhibition in luminescence in the livers of mice 
in the RSM (100 mg/kg, 200 mg/kg) group compared to 
that in the control group, as visualized using Xenogen 
imaging (Fig.  11a). The nude mice were sacrificed after 
4 weeks and the size of orthotopic liver transplantations 
were measured in each group. The tumor volume of the 
orthotopic liver transplantation decreased significantly 
after RSM treatment (P < 0.05) (Fig. 11b).
Discussion
In this study, RSM inhibited cellular proliferation, inva-
sion, and migration, and induced cell cycle arrest at the 
G2/M phase and cellular apoptosis associated with HCC 
in  vitro through modulation of the PI3K/AKT pathway 
and EGFR. RSM is one of the most popular Chinese 
medicinal herbs. Studies have demonstrated that RSM or 
RSM extracts may have positive effects in patients with 
liver fibrosis [41, 42], dementia [43–45], osteoporosis 
[46], chronic renal failure [47–49], and fulminant hepatic 
failure [50]. Previous research has shown that RSM 
extracts inhibit proliferation and induce apoptosis in 
HepG2 cells [51]. However, the underlying mechanisms 
of the pharmacological action of RSM in HCC therapy 
remain unclear.
We analyzed the putative active compounds and tar-
gets of RSM through a network pharmacology approach, 
a powerful tool that has emerged to better understand 
the underlying mechanisms of action of TCM. To elu-
cidate the pharmacological mechanism of RSM acting 
Fig. 7 RSM inhibits cell viability. a Viability of MHCC97‑H and b HepG2 cells following 24 h incubation with the indicated doses of RSM. All data are 
presented as mean ± standard deviation (SD; n = 4). c Colony formation assay was performed using MHCC97‑H and HepG2 cells treated with RSM. 
A representative of three experiments is shown. d Colony formation is presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001 versus the 
control group
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on human HCC, we performed a PPI network analysis. 
The PPI network analysis revealed that TNF, PIK3CG, 
VEGFA, IL6, EGFR, MAPK1, JUN, TP53, BCL2, and 
ESR1 may represent hub genes against HCC. EGFR is a 
transmembrane receptor tyrosine kinase and a receptor 
for members of the ErbB family of extracellular protein 
ligands [52]. EGFR signaling modulates diverse cell func-
tions and promotes cellular proliferation, differentiation, 
migration, growth, and survival [53]. Mutations in EFGR 
lead to its overexpression (upregulation or amplification), 
which is associated with many cancers, including lung 
cell carcinoma [54], glioblastoma [55], anal cancer [56], 
and epithelial tumors in the head and neck [57]. Previous 
studies have indicated that EGFR activation plays a piv-
otal role in the development of HCC [58, 59]; however, 
there is no evidence to support the downregulation of 
EGFR expression by RSM. In this study, we evaluated 
EGFR expression in MHCC97-H and HepG2 cells. The 
results showed that RSM could decrease EGFR expres-
sion in a dose-dependent manner compared to that in the 
control group. Furthermore, EGFR is also an upstream 
protein in the PI3K/AKT signal transduction pathway, 
which is an important target in cancer research [60, 61].
The pathway analysis results obtained by DAVID sug-
gested that pathways in cancer, PI3K/AKT signaling 
pathway, and proteoglycans in cancer may be closely 
Fig. 8 RSM induces apoptosis and cell cycle G2/M arrest in MHCC97‑H and HepG2 cells. a Flow cytometric analysis of Annexin V/PI double staining 
in MHCC97‑H and HepG2 cells treated with various concentrations of RSM for 24 h. b MHCC97‑H and HepG2 cells were treated with RSM at the 
indicated concentrations for 24 h and subjected to western blotting with antibodies against Bcl‑2 and Bax. c Cell cycle analysis revealed that RSM 
arrested cells at the G2/M checkpoint. MHCC97‑H and HepG2 cells were incubated with the indicated dose of RSM for 24 h, stained with Propidium 
iodide (PI), and DNA content was analyzed via flow cytometry. All data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001 versus 
the control group
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related to HCC progression. Phosphatidylinositol-3-ki-
nases (PI3Ks) are a family of enzymes that phosphoryl-
ate the 3-position hydroxyl group of the inositol ring 
of phosphatidylinositol. PI3K contains two domains: a 
catalytic domain, P110, and a regulatory domain, P85 
[62]. AKT, also referred to as protein kinase B, is a ser-
ine/threonine-specific protein kinase that plays a critical 
role in multiple cellular processes. The PI3K/AKT signal-
ing pathway plays a key role in normal cellular processes 
involved in growth, glucose metabolism, proliferation, 
survival, apoptosis, motility, ribosomal function, gene 
transcription, migration, and invasion, via phospho-
rylation of a variety of substrates by the serine/threo-
nine kinase AKT [63, 64]. A growing body of evidence 
suggests that aberrant activation of the PI3K/AKT path-
way promotes the development and progression of mul-
tiple human malignancies [65, 66], such as lung cancer 
[67], ovarian cancer [68], and oral squamous cell carci-
noma [69]. Cryptotanshinone, a natural active compound 
of S. miltiorrhiza Bunge, has been shown to affect cell 
cycle arrest and apoptosis through the PI3K/Akt/NFκB 
and JAK2/STAT3 pathways in cholangiocarcinoma cells 
[70]. Tanshinone IIA, one of the main compounds of S. 
miltiorrhiza Bunge, has been shown to inhibit the growth 
of cancer cells via autophagy and apoptosis, which is 
related to the Beclin-1/Atg7/Atg12-Atg5 and PI3K/Akt/
mTOR pathways [71]. In the present study, high expres-
sion of phosphorylate AKT (p-AKT) and PI3K in the 
Fig. 9 RSM inhibits the migration and invasion of MHCC97‑H and HepG2 cells. a Effects of RSM on the migration of MHCC97‑H and HepG2 cells 
as shown by a wound healing assay. The cell surface was wounded and cells were photographed at 0 and 48 h (×100 magnification). b Transwell 
migration and invasion assays were performed to determine the effect of RSM on cell migration and invasion. Invading and migrating cells were 
photographed (×100 magnification). All data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001 versus the control group
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control group indicated the activation of the PI3K/AKT 
signal transduction pathway. Compared to levels in the 
control group, the levels of p-AKT and PI3K in the treat-
ment group were significantly decreased, and the expres-
sion of total AKT remained constant. Therefore, our 
results revealed that RSM plays a significant anti-HCC 
role, which is mediated by the PI3K/AKT pathway.
This study demonstrates, for the first time, that 
RSM can efficiently suppress cellular proliferation 
and induce G2/M checkpoint arrest and apoptosis. 
In addition, RSM also affects the migration and inva-
sion ability of MHCC97-H and HepG2 cells. Taken 
together, our results indicate that RSM acts on HCC 
through the EGFR and PI3K/AKT signaling pathways. 
Due to budgetary and time constraints, only a few key 
molecules and mechanisms involved in the antitumor 
activity of RSM on HCC were studied here. Therefore, 
other potential mechanisms that may underly the anti-
tumor action of RSM in vitro and in vivo await further 
elucidation. Despite its limitations, this study provides 
powerful and preliminary data to support the future 
evaluation of RSM in HCC. RSM may be a potential 
anti-HCC inhibitor, which can be developed as a ther-
apeutic option for the treatment of cancer.
Conclusions
Taken together, our studies illustrate that RSM could 
suppress proliferation, induce G2/M checkpoint arrest 
and apoptosis, and impair the migration and invasion 
ability of MHCC97-H and HepG2 cells in vitro, which 
may be linked to the EGFR and PI3K/AKT signaling 
pathways. In addition, RSM could inhibit liver tumor 
growth of orthotopically implanted HCC in nude mice.
Fig. 10 RSM down‑regulates EGFR expression, and attenuates PI3K/AKT signaling in human HCC cells. Western blot analysis of EGFR, PI3K, AKT, and 
p‑AKT in a MHCC97‑H and b HepG2 cells. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001 versus the control group
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